KEYMED BIO-B (02162) Reports Interim Results with Shareholder Loss of RMB 78.84 Million, Narrowing by 76.59% Year-on-Year
Stock News
Aug 26
KEYMED BIO-B (02162) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 499 million, representing a year-on-year increase of 812.1%. The loss attributable to shareholders was RMB 78.84 million, narrowing by 76.59% compared to the same period last year. Basic loss per share was RMB 0.3.
According to the announcement, during the reporting period, the Group's revenue comprised collaboration revenue and sales of spumacizumab (Kayerta). Collaboration revenue amounted to RMB 329 million, while spumacizumab sales reached RMB 169 million. Cost of sales included production costs of spumacizumab and costs arising from out-licensing collaboration arrangements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.